Jynneos market forecast points to steady growth through 2035

The Jynneos vaccine market is projected to keep expanding as monkeypox concerns, biodefense spending and adult immunization programs widen demand. North America led the market in 2025, while Europe is expected to grow fastest through the forecast period.

Why it matters: - The Jynneos market is tied to preparedness for monkeypox, smallpox and other emerging zoonotic threats. - Rising case counts and public stockpiling are pushing governments and health systems to keep vaccine supply ready. - The market trend also reflects wider demand for non-replicating vaccines that are safer for immunocompromised people.

What happened: - The Business Research Company released its Jynneos Market Global Market Report 2026 – Market Size, Trends, and Forecast 2026-2035 on Nov. 5, 2026. - The report says the Jynneos market has grown on the back of smallpox eradication efforts, prior monkeypox outbreaks, safer vaccinia-based vaccines, government preparedness programs and public vaccination campaigns. - The report expects continued expansion from higher zoonotic disease risk, larger national vaccine stockpiles, more biodefense funding, better disease surveillance and broader adult immunization programs. - The report says the market is shaped by growing prevention efforts, non-replicating vaccine platforms, government immunization initiatives, strategic vaccine stockpiles and greater awareness of zoonotic infections.

The details: - Jynneos is a vaccine designed to protect against monkeypox and smallpox. - Jynneos uses a modified vaccinia virus that does not replicate in the body but still prompts an immune response. - The non-replicating design makes Jynneos a safer alternative to traditional smallpox vaccines, especially for people with weakened immune systems. - Monkeypox cases remain a major demand driver for the vaccine market. - By September 2024, the European Centre for Disease Prevention and Control reported more than 100,000 confirmed monkeypox cases in more than 120 countries since January 2022, along with more than 200 deaths. - The report highlights combination vaccines as an important market trend because they can reduce the number of injections and improve immunization efficiency. - In August 2024, Bavarian Nordic A/S said Singapore’s Health Sciences Authority approved JYNNEOS (MVA-BN) for preventing smallpox and pox in adults 18 and older who are at high risk. - The approval underscores demand for non-replicating vaccine options for higher-risk and immunocompromised populations. - North America held the largest share of the Jynneos market in 2025. - Europe is projected to be the fastest-growing region through the forecast period. - The report covers Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa.

Between the lines: - The market outlook suggests Jynneos is becoming less of a niche outbreak product and more of a standing public-health tool. - Stockpiling and surveillance spending point to a defense-style procurement model, where governments buy before crises rather than after them. - The combination-vaccine trend signals that buyers want simpler immunization programs, not just more doses.

What's next: - The report expects growth to continue through 2035 as governments expand preparedness programs and adult vaccination efforts. - Future demand will likely depend on monkeypox surveillance, vaccine stockpile policy and regional public-health funding. - The Business Research Company added market attractiveness scoring, TAM analysis, company scoring matrix graphics, Excel forecasting dashboards, market hotspots infographics, key technologies and updated graphics to its 2026 report set. - The company also published a free sample and a full report for Jynneos market coverage: Download a free sample of the Jynneos market report and View the full Jynneos market report.

The bottom line: - Jynneos demand is being driven by outbreak risk, public stockpiling and broader immunization planning, with North America leading today and Europe poised for the fastest growth.